Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer

Tushar D. Bhagat, Yiyu Zou, Shizheng Huang, Jihwan Park, Matthew B. Palmer, Caroline Hu, Weijuan Li, Niraj Shenoy, Orsolya Giricz, Gaurav Choudhary, Yiting Yu, Yi An Ko, María C. Izquierdo, Ae Seo Deok Park, Nishanth Vallumsetla, Remi Laurence, Robert Lopez, Masako Suzuki, James M. Pullman, Justin KanerBenjamin A. Gartrell, A. Ari Hakimi, John M. Greally, Bharvin Patel, Karim Benhadji, Kith Pradhan, Amit K. Verma, Katalin Susztak

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy in advanced stages and needs newer therapeutic targets. Transcriptomic analysis of CCRCCs and matched microdissected renal tubular controls revealed overexpression of NOTCH ligands and receptors in tumor tissues. Examination of the TCGA RNA-seq data set also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples. Samples with NOTCH pathway activation were also clinically distinct and were associated with better overall survival. Parallel DNA methylation and copy number analysis demonstrated that both genetic and epigenetic alterations led to NOTCH pathway activation in CCRCC. NOTCH ligand JAGGED1 was overexpressed and associated with loss of CpG methylation of H3K4me1-associated enhancer regions. JAGGED2 was also overexpressed and associated with gene amplification in distinct CCRCC samples. Transgenic expression of intracellular NOTCH1 in mice with tubule-specific deletion of VHL led to dysplastic hyperproliferation of tubular epithelial cells, confirming the procarcinogenic role of NOTCH in vivo. Alteration of cell cycle pathways was seen in murine renal tubular cells with NOTCH overexpression, and molecular similarity to human tumors was observed, demonstrating that human CCRCC recapitulates features and gene expression changes observed in mice with transgenic overexpression of the Notch intracellular domain. Treatment with the γ-secretase inhibitor LY3039478 led to inhibition of CCRCC cells in vitro and in vivo. In summary, these data reveal the mechanistic basis of NOTCH pathway activation in CCRCC and demonstrate this pathway to a potential therapeutic target.

Original languageEnglish (US)
Pages (from-to)837-846
Number of pages10
JournalJournal of Biological Chemistry
Volume292
Issue number3
DOIs
StatePublished - Jan 20 2017

Fingerprint

Renal Cell Carcinoma
Epigenomics
Chemical activation
Tumors
Cells
Ligands
Amyloid Precursor Protein Secretases
Methylation
Therapeutics
Gene expression
Kidney
Neoplasms
RNA
Tissue
Gene Amplification
DNA Methylation
Transgenic Mice
Cell Cycle
Epithelial Cells
Gene Expression

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. / Bhagat, Tushar D.; Zou, Yiyu; Huang, Shizheng; Park, Jihwan; Palmer, Matthew B.; Hu, Caroline; Li, Weijuan; Shenoy, Niraj; Giricz, Orsolya; Choudhary, Gaurav; Yu, Yiting; Ko, Yi An; Izquierdo, María C.; Park, Ae Seo Deok; Vallumsetla, Nishanth; Laurence, Remi; Lopez, Robert; Suzuki, Masako; Pullman, James M.; Kaner, Justin; Gartrell, Benjamin A.; Hakimi, A. Ari; Greally, John M.; Patel, Bharvin; Benhadji, Karim; Pradhan, Kith; Verma, Amit K.; Susztak, Katalin.

In: Journal of Biological Chemistry, Vol. 292, No. 3, 20.01.2017, p. 837-846.

Research output: Contribution to journalArticle

Bhagat, TD, Zou, Y, Huang, S, Park, J, Palmer, MB, Hu, C, Li, W, Shenoy, N, Giricz, O, Choudhary, G, Yu, Y, Ko, YA, Izquierdo, MC, Park, ASD, Vallumsetla, N, Laurence, R, Lopez, R, Suzuki, M, Pullman, JM, Kaner, J, Gartrell, BA, Hakimi, AA, Greally, JM, Patel, B, Benhadji, K, Pradhan, K, Verma, AK & Susztak, K 2017, 'Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer', Journal of Biological Chemistry, vol. 292, no. 3, pp. 837-846. https://doi.org/10.1074/jbc.M116.745208
Bhagat, Tushar D. ; Zou, Yiyu ; Huang, Shizheng ; Park, Jihwan ; Palmer, Matthew B. ; Hu, Caroline ; Li, Weijuan ; Shenoy, Niraj ; Giricz, Orsolya ; Choudhary, Gaurav ; Yu, Yiting ; Ko, Yi An ; Izquierdo, María C. ; Park, Ae Seo Deok ; Vallumsetla, Nishanth ; Laurence, Remi ; Lopez, Robert ; Suzuki, Masako ; Pullman, James M. ; Kaner, Justin ; Gartrell, Benjamin A. ; Hakimi, A. Ari ; Greally, John M. ; Patel, Bharvin ; Benhadji, Karim ; Pradhan, Kith ; Verma, Amit K. ; Susztak, Katalin. / Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. In: Journal of Biological Chemistry. 2017 ; Vol. 292, No. 3. pp. 837-846.
@article{9d0fd17bfbd1463bb07f5d8c07914fd9,
title = "Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer",
abstract = "Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy in advanced stages and needs newer therapeutic targets. Transcriptomic analysis of CCRCCs and matched microdissected renal tubular controls revealed overexpression of NOTCH ligands and receptors in tumor tissues. Examination of the TCGA RNA-seq data set also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples. Samples with NOTCH pathway activation were also clinically distinct and were associated with better overall survival. Parallel DNA methylation and copy number analysis demonstrated that both genetic and epigenetic alterations led to NOTCH pathway activation in CCRCC. NOTCH ligand JAGGED1 was overexpressed and associated with loss of CpG methylation of H3K4me1-associated enhancer regions. JAGGED2 was also overexpressed and associated with gene amplification in distinct CCRCC samples. Transgenic expression of intracellular NOTCH1 in mice with tubule-specific deletion of VHL led to dysplastic hyperproliferation of tubular epithelial cells, confirming the procarcinogenic role of NOTCH in vivo. Alteration of cell cycle pathways was seen in murine renal tubular cells with NOTCH overexpression, and molecular similarity to human tumors was observed, demonstrating that human CCRCC recapitulates features and gene expression changes observed in mice with transgenic overexpression of the Notch intracellular domain. Treatment with the γ-secretase inhibitor LY3039478 led to inhibition of CCRCC cells in vitro and in vivo. In summary, these data reveal the mechanistic basis of NOTCH pathway activation in CCRCC and demonstrate this pathway to a potential therapeutic target.",
author = "Bhagat, {Tushar D.} and Yiyu Zou and Shizheng Huang and Jihwan Park and Palmer, {Matthew B.} and Caroline Hu and Weijuan Li and Niraj Shenoy and Orsolya Giricz and Gaurav Choudhary and Yiting Yu and Ko, {Yi An} and Izquierdo, {Mar{\'i}a C.} and Park, {Ae Seo Deok} and Nishanth Vallumsetla and Remi Laurence and Robert Lopez and Masako Suzuki and Pullman, {James M.} and Justin Kaner and Gartrell, {Benjamin A.} and Hakimi, {A. Ari} and Greally, {John M.} and Bharvin Patel and Karim Benhadji and Kith Pradhan and Verma, {Amit K.} and Katalin Susztak",
year = "2017",
month = "1",
day = "20",
doi = "10.1074/jbc.M116.745208",
language = "English (US)",
volume = "292",
pages = "837--846",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "3",

}

TY - JOUR

T1 - Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer

AU - Bhagat, Tushar D.

AU - Zou, Yiyu

AU - Huang, Shizheng

AU - Park, Jihwan

AU - Palmer, Matthew B.

AU - Hu, Caroline

AU - Li, Weijuan

AU - Shenoy, Niraj

AU - Giricz, Orsolya

AU - Choudhary, Gaurav

AU - Yu, Yiting

AU - Ko, Yi An

AU - Izquierdo, María C.

AU - Park, Ae Seo Deok

AU - Vallumsetla, Nishanth

AU - Laurence, Remi

AU - Lopez, Robert

AU - Suzuki, Masako

AU - Pullman, James M.

AU - Kaner, Justin

AU - Gartrell, Benjamin A.

AU - Hakimi, A. Ari

AU - Greally, John M.

AU - Patel, Bharvin

AU - Benhadji, Karim

AU - Pradhan, Kith

AU - Verma, Amit K.

AU - Susztak, Katalin

PY - 2017/1/20

Y1 - 2017/1/20

N2 - Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy in advanced stages and needs newer therapeutic targets. Transcriptomic analysis of CCRCCs and matched microdissected renal tubular controls revealed overexpression of NOTCH ligands and receptors in tumor tissues. Examination of the TCGA RNA-seq data set also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples. Samples with NOTCH pathway activation were also clinically distinct and were associated with better overall survival. Parallel DNA methylation and copy number analysis demonstrated that both genetic and epigenetic alterations led to NOTCH pathway activation in CCRCC. NOTCH ligand JAGGED1 was overexpressed and associated with loss of CpG methylation of H3K4me1-associated enhancer regions. JAGGED2 was also overexpressed and associated with gene amplification in distinct CCRCC samples. Transgenic expression of intracellular NOTCH1 in mice with tubule-specific deletion of VHL led to dysplastic hyperproliferation of tubular epithelial cells, confirming the procarcinogenic role of NOTCH in vivo. Alteration of cell cycle pathways was seen in murine renal tubular cells with NOTCH overexpression, and molecular similarity to human tumors was observed, demonstrating that human CCRCC recapitulates features and gene expression changes observed in mice with transgenic overexpression of the Notch intracellular domain. Treatment with the γ-secretase inhibitor LY3039478 led to inhibition of CCRCC cells in vitro and in vivo. In summary, these data reveal the mechanistic basis of NOTCH pathway activation in CCRCC and demonstrate this pathway to a potential therapeutic target.

AB - Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy in advanced stages and needs newer therapeutic targets. Transcriptomic analysis of CCRCCs and matched microdissected renal tubular controls revealed overexpression of NOTCH ligands and receptors in tumor tissues. Examination of the TCGA RNA-seq data set also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples. Samples with NOTCH pathway activation were also clinically distinct and were associated with better overall survival. Parallel DNA methylation and copy number analysis demonstrated that both genetic and epigenetic alterations led to NOTCH pathway activation in CCRCC. NOTCH ligand JAGGED1 was overexpressed and associated with loss of CpG methylation of H3K4me1-associated enhancer regions. JAGGED2 was also overexpressed and associated with gene amplification in distinct CCRCC samples. Transgenic expression of intracellular NOTCH1 in mice with tubule-specific deletion of VHL led to dysplastic hyperproliferation of tubular epithelial cells, confirming the procarcinogenic role of NOTCH in vivo. Alteration of cell cycle pathways was seen in murine renal tubular cells with NOTCH overexpression, and molecular similarity to human tumors was observed, demonstrating that human CCRCC recapitulates features and gene expression changes observed in mice with transgenic overexpression of the Notch intracellular domain. Treatment with the γ-secretase inhibitor LY3039478 led to inhibition of CCRCC cells in vitro and in vivo. In summary, these data reveal the mechanistic basis of NOTCH pathway activation in CCRCC and demonstrate this pathway to a potential therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=85010031090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010031090&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.745208

DO - 10.1074/jbc.M116.745208

M3 - Article

C2 - 27909050

AN - SCOPUS:85010031090

VL - 292

SP - 837

EP - 846

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 3

ER -